ArticleCancer science2012

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.

Isamu Okamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.